| Edge intelligence: The confluence of edge computing and artificial intelligence S Deng, H Zhao, W Fang, J Yin, S Dustdar, AY Zomaya IEEE Internet of Things Journal 7 (8), 7457-7469, 2020 | 1014 | 2020 |
| Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial S Qin, Z Ren, Z Meng, Z Chen, X Chai, J Xiong, Y Bai, L Yang, H Zhu, ... The Lancet Oncology 21 (4), 571-580, 2020 | 565 | 2020 |
| Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma Y Zheng, T Wang, X Tu, Y Huang, H Zhang, DI Tan, W Jiang, S Cai, ... Journal for immunotherapy of cancer 7, 1-7, 2019 | 440 | 2019 |
| Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study S Qin, SL Chan, S Gu, Y Bai, Z Ren, X Lin, Z Chen, W Jia, Y Jin, Y Guo, ... The Lancet 402 (10408), 1133-1146, 2023 | 334 | 2023 |
| Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial S Qin, Q Li, S Gu, X Chen, L Lin, Z Wang, A Xu, X Chen, C Zhou, Z Ren, ... The lancet Gastroenterology & hepatology 6 (7), 559-568, 2021 | 226 | 2021 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 187 | 2023 |
| Pembrolizumab versus placebo as second-line therapy in patients from Asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial S Qin, Z Chen, W Fang, Z Ren, R Xu, BY Ryoo, Z Meng, Y Bai, X Chen, ... Journal of Clinical Oncology 41 (7), 1434-1443, 2023 | 131 | 2023 |
| Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial F Wang, S Qin, X Sun, Z Ren, Z Meng, Z Chen, X Chai, J Xiong, Y Bai, ... Journal of hematology & oncology 13, 1-10, 2020 | 125 | 2020 |
| Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC X Bao, R Shi, T Zhao, Y Wang, N Anastasov, M Rosemann, W Fang Cancer Immunology, Immunotherapy 70, 189-202, 2021 | 120 | 2021 |
| Molecular epidemiology of Clostridium difficile infection in hospitalized patients in eastern China D Jin, Y Luo, C Huang, J Cai, J Ye, Y Zheng, L Wang, P Zhao, A Liu, ... Journal of clinical microbiology 55 (3), 801-810, 2017 | 119 | 2017 |
| Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase … S Qin, Z Chen, W Fang, Z Ren, R Xu, BY Ryoo, Z Meng, Y Bai, X Chen, ... Journal of Clinical Oncology 40 (4_suppl), 383-383, 2022 | 117 | 2022 |
| Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer B Xu, L Yuan, Q Gao, P Yuan, P Zhao, H Yuan, H Fan, T Li, P Qin, L Han, ... Oncotarget 6 (24), 20592, 2015 | 106 | 2015 |
| Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition) J Li, Y Yuan, F Yang, Y Wang, X Zhu, Z Wang, S Zheng, D Wan, J He, ... Journal of hematology & oncology 12, 1-11, 2019 | 101 | 2019 |
| SCAU-net: spatial-channel attention U-net for gland segmentation P Zhao, J Zhang, W Fang, S Deng Frontiers in Bioengineering and Biotechnology 8, 670, 2020 | 97 | 2020 |
| Construction of TME and identification of crosstalk between malignant cells and macrophages by SPP1 in hepatocellular carcinoma L Liu, R Zhang, J Deng, X Dai, X Zhu, Q Fu, H Zhang, Z Tong, P Zhao, ... Cancer Immunology, Immunotherapy 71 (1), 121-136, 2022 | 88 | 2022 |
| Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients H Shen, Y Yuan, HG Hu, X Zhong, XX Ye, MD Li, WJ Fang, S Zheng World journal of gastroenterology: WJG 17 (6), 809, 2011 | 86 | 2011 |
| Anti–PD-1/PD-L1 blockade immunotherapy employed in treating hepatitis B virus infection–related advanced hepatocellular carcinoma: a literature review B Li, C Yan, J Zhu, X Chen, Q Fu, H Zhang, Z Tong, L Liu, Y Zheng, ... Frontiers in Immunology 11, 1037, 2020 | 84 | 2020 |
| Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy X Bao, H Zhang, W Wu, S Cheng, X Dai, X Zhu, Q Fu, Z Tong, L Liu, ... Journal for immunotherapy of cancer 8 (2), 2020 | 84 | 2020 |
| Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases J Sun, C Wang, Y Zhang, L Xu, W Fang, Y Zhu, Y Zheng, X Chen, X Xie, ... Nature communications 10 (1), 3190, 2019 | 79 | 2019 |
| A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin Y Zheng, X Tu, P Zhao, W Jiang, L Liu, Z Tong, H Zhang, C Yan, W Fang, ... British Journal of Cancer 119 (3), 291-295, 2018 | 68 | 2018 |